Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3381.00 | 27,579 Cr | 71.41 | 16.68 | 0.07 | 21.54 | 28.77 | 19.52 | ||
1289.10 | 27,347 Cr | 78.38 | 11.01 | 0.00 | 14.05 | 18.23 | 9.62 | ||
1562.25 | 25,837 Cr | 104.71 | 20.05 | 0.10 | 19.14 | 22.56 | 10.60 | ||
192.05 | 25,569 Cr | -78.45 | 3.13 | 0.00 | -3.58 | 2.58 | -1.81 | ||
19020.25 | 24,345 Cr | 66.88 | 12.99 | 0.18 | 19.42 | 23.57 | 12.42 | ||
4708.70 | 21,456 Cr | 29.70 | 5.11 | 1.60 | 17.19 | 23.02 | 14.68 | ||
843.80 | 20,878 Cr | 31.52 | 4.42 | 0.21 | 11.70 | 13.63 | 8.58 | ||
| Median: 7 Co. | — | 1562.25 | 25,569 Cr | 66.88 | 11.01 | 0.10 | 17.19 | 22.56 | 10.60 |
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Piramal Pharma Limited is a global pharmaceutical company operating three principal verticals—an integrated CDMO (Piramal Pharma Solutions), Complex Hospital Generics (Piramal Critical Care), and India Consumer Healthcare—providing end-to-end manufacturing across 17 facilities and selling across 100+ countries through differentiated capabilities in HP APIs, ADCs, sterile injectables, biologics, and ICH OTC brands.
Q3 FY'26 and nine-month results show muted revenue performance with reported revenues of approximately Rs. 2,140 crores for the quarter and Rs. 6,117 crores for nine months, a year-on-year decline, while EBITDA margins were resilient at ~11% for the quarter and ~10% for nine months due to cost optimisation and operational excellence.
The CDMO business is showing leading indicators of recovery: management reported a marked increase in RFPs and order inflows since October 2025 driven by a rebound in U.S. biopharma funding and M&A activity, while management reaffirmed long‑range targets and continues to invest in onshore, higher‑margin capacity.
Complex Hospital Generics remains a high‑margin anchor, with Sevoflurane U.S. market share rising to 47% and intrathecal Baclofen holding a 75% share in the U.S.; management is pursuing disciplined ROW commercialization from Digwal and selective inorganic additions such as Kenalog to broaden the CHG portfolio without significant incremental operating cost.
India Consumer Healthcare is a growth engine with PCH sales up ~20% in Q3 and 16% over nine months, power brands growing ~30% in Q3, and e‑commerce expanding over 50% year to date and now contributing 26% of PCH sales, highlighting successful digital distribution and brand scaling execution.
Pharmaceuticals & Biotechnology
Pharmaceuticals
25,569 Cr
High Risk
-78.5
37.2
—
3.1
210.35
132.50
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Jul 28, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Piramal Pharma Ltd (PPLPHARMA) is currently trading at 193.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Piramal Pharma Limited is a global pharmaceutical company operating three principal verticals—an integrated CDMO (Piramal Pharma Solutions), Complex Hospital Generics (Piramal Critical Care), and India Consumer Healthcare—providing end-to-end manufacturing across 17 facilities and selling across 100+ countries through differentiated capabilities in HP APIs, ADCs, sterile injectables, biologics, and ICH OTC brands. Q3 FY'26 and nine-month results show muted revenue performance with reported revenues of approximately Rs. 2,140 crores for the quarter and Rs. 6,117 crores for nine months, a year-on-year decline, while EBITDA margins were resilient at ~11% for the quarter and ~10% for nine months due to cost optimisation and operational excellence. The CDMO business is showing leading indicators of recovery: management reported a marked increase in RFPs and order inflows since October 2025 driven by a rebound in U.S. biopharma funding and M&A activity, while management reaffirmed long‑range targets and continues to invest in onshore, higher‑margin capacity. Complex Hospital Generics remains a high‑margin anchor, with Sevoflurane U.S. market share rising to 47% and intrathecal Baclofen holding a 75% share in the U.S.; management is pursuing disciplined ROW commercialization from Digwal and selective inorganic additions such as Kenalog to broaden the CHG portfolio without significant incremental operating cost. India Consumer Healthcare is a growth engine with PCH sales up ~20% in Q3 and 16% over nine months, power brands growing ~30% in Q3, and e‑commerce expanding over 50% year to date and now contributing 26% of PCH sales, highlighting successful digital distribution and brand scaling execution.
Over the past 52 weeks, Piramal Pharma Ltd has traded between a low of ₹132.50 and a high of ₹210.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Piramal Pharma Ltd has a market capitalization of approximately 25,568.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Piramal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -78.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 25,568.54 Cr, Piramal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Piramal Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Piramal Pharma Ltd is -78.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
An EIR indicates the US FDA has formally closed the inspection and found the facility’s operations compliant with cGMP, as described in the provided material.
The company is targeting $200 million in revenue by 2030, according to CEO Sai Ramana Ponugoti’s comments to Mint and a company profile note.
The stock surged after Piramal Pharma said it received over 70 regulatory approvals across its global network in the past fiscal year.
The Piramal Pharma share price was ₹195.64 as on 12 Nov 2025.
Bearish
8
Neutral
1
Bullish
5
Bearish
8
Neutral
1
Bullish
37
Bearish
0
Neutral
0
Bullish
32
